CN110177564A - 多价的调节t细胞调节剂 - Google Patents

多价的调节t细胞调节剂 Download PDF

Info

Publication number
CN110177564A
CN110177564A CN201780076808.XA CN201780076808A CN110177564A CN 110177564 A CN110177564 A CN 110177564A CN 201780076808 A CN201780076808 A CN 201780076808A CN 110177564 A CN110177564 A CN 110177564A
Authority
CN
China
Prior art keywords
seq
protein
amino acid
domain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780076808.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·格雷沃
J·金
N·纳加拉詹
J·赵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delhi Corp
Original Assignee
Delhi Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delhi Corp filed Critical Delhi Corp
Publication of CN110177564A publication Critical patent/CN110177564A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
CN201780076808.XA 2016-12-13 2017-12-13 多价的调节t细胞调节剂 Pending CN110177564A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662433533P 2016-12-13 2016-12-13
US62/433,533 2016-12-13
PCT/US2017/066163 WO2018112069A1 (en) 2016-12-13 2017-12-13 Multivalent regulatory t cell modulators

Publications (1)

Publication Number Publication Date
CN110177564A true CN110177564A (zh) 2019-08-27

Family

ID=62488540

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780076808.XA Pending CN110177564A (zh) 2016-12-13 2017-12-13 多价的调节t细胞调节剂

Country Status (11)

Country Link
US (2) US10472405B2 (https=)
EP (1) EP3554525A4 (https=)
JP (1) JP7228515B2 (https=)
KR (1) KR20190094222A (https=)
CN (1) CN110177564A (https=)
AU (1) AU2017378308A1 (https=)
BR (2) BR112019011799B1 (https=)
CA (1) CA3044416A1 (https=)
MX (2) MX381276B (https=)
RU (1) RU2769871C2 (https=)
WO (1) WO2018112069A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021093633A1 (zh) * 2019-09-10 2021-05-20 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840545B2 (en) 2013-09-20 2017-12-12 University Of Virginia Patent Foundation Fusion protein comprising interleukin-2 and interleukin-33
AU2017378308A1 (en) 2016-12-13 2019-06-20 Delinia, Inc. Multivalent regulatory T cell modulators
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
BR112021002250A2 (pt) 2018-08-06 2021-07-20 Medikine, Inc. compostos de ligação ao receptor de il-2
AU2019369498A1 (en) * 2018-10-31 2021-05-20 Delinia, Inc. Multivalent regulatory T cell modulators
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
IL292803A (en) 2019-11-05 2022-07-01 Medikine Inc Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof
JP7427286B2 (ja) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド ＩＬ－２ＲβγＣ結合化合物
MX2022009302A (es) 2020-02-03 2022-11-16 Medikine Inc Compuestos de unión a il-7r¿.
CA3166816A1 (en) 2020-02-03 2021-08-12 William J. Dower Il-7r.alpha..gamma.c binding compounds
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
CA3247209A1 (en) * 2022-05-11 2023-11-16 Slate Bio, Inc. COMPOSITIONS COMPRISING INTERLEUKIN-2 AND TRUNCATED INTERLEUKIN-33
WO2025106677A1 (en) * 2023-11-15 2025-05-22 Slate Bio, Inc. Bifunctional il-2 and il-33 proteins for treating autoimmune disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754855B1 (en) * 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
WO2015042521A1 (en) * 2013-09-20 2015-03-26 University Of Virginia Patent Foundation Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
US20150307594A1 (en) * 2012-11-28 2015-10-29 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2016014428A2 (en) * 2014-07-21 2016-01-28 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US20050089517A1 (en) 2003-09-23 2005-04-28 Shames Richard S. Treatment of respiratory diseases with anti-IL-2 receptor antibodies
AR091069A1 (es) * 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
AU2013289883B2 (en) * 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
EP2970486B1 (en) * 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
AU2017378308A1 (en) 2016-12-13 2019-06-20 Delinia, Inc. Multivalent regulatory T cell modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754855B1 (en) * 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US20150307594A1 (en) * 2012-11-28 2015-10-29 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2015042521A1 (en) * 2013-09-20 2015-03-26 University Of Virginia Patent Foundation Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
US20160304574A1 (en) * 2013-09-20 2016-10-20 University Of Virginia Patent Foundation Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
WO2016014428A2 (en) * 2014-07-21 2016-01-28 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021093633A1 (zh) * 2019-09-10 2021-05-20 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用

Also Published As

Publication number Publication date
EP3554525A1 (en) 2019-10-23
AU2017378308A1 (en) 2019-06-20
JP2020501550A (ja) 2020-01-23
RU2019121902A3 (https=) 2021-04-21
JP7228515B2 (ja) 2023-02-24
KR20190094222A (ko) 2019-08-12
US10472405B2 (en) 2019-11-12
WO2018112069A1 (en) 2018-06-21
BR112019011799B1 (pt) 2021-12-21
US20200031897A1 (en) 2020-01-30
EP3554525A4 (en) 2020-08-19
BR122020025384B1 (pt) 2022-07-12
MX381276B (es) 2025-03-12
US20180162919A1 (en) 2018-06-14
MX2021004007A (es) 2021-06-23
BR112019011799A2 (pt) 2019-10-29
MX2019007002A (es) 2019-08-22
RU2769871C2 (ru) 2022-04-07
US11059877B2 (en) 2021-07-13
RU2019121902A (ru) 2021-01-18
CA3044416A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
JP7228515B2 (ja) 多価制御性ｔ細胞調節因子
US20210403579A1 (en) Multivalent regulatory t cell modulators
AU2020203196A1 (en) Combination therapies and uses for treatment of demyelinating disorders
KR102840867B1 (ko) 치료용 항-cd40 리간드 항체
US12577310B2 (en) Caninized antibodies to canine interleukin-31 receptor alpha
US12545738B2 (en) Canine interleukin-4 receptor alpha antibodies
JP2023500066A (ja) ＴＧＦ－βポリペプチド
JP2024512714A (ja) 融合タンパク質、医薬組成物、及び治療適用
JP2021522274A (ja) Ｃｄ１２３及びｃｄ３に結合する二重特異性抗体の投与
US20250122285A1 (en) Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications
JP2025500805A (ja) ヒトｎｇｆに対するイヌ化およびネコ化抗体
JP2024526080A (ja) インターロイキン１５多様体
CN116472287A (zh) 犬白介素-31受体α的犬源化抗体
HK40008615A (en) Multivalent regulatory t cell modulators
RU2854627C1 (ru) Биспецифические канинизированные антитела для лечения атопического дерматита
HK40052681A (en) Multivalent regulatory t cell modulators
CN118401549A (zh) 人ngf的犬源化和猫源化抗体
CN117999289A (zh) 具有延长的半衰期的抗体和IgG融合蛋白

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008615

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190827

WD01 Invention patent application deemed withdrawn after publication